团队依托同济大学附属肺科医院，深耕胸部肿瘤精准诊治多年，以提高肺癌早诊率、克服常见靶向治疗耐药并研发少见靶点的靶向药物，及研发精准免疫治疗新策略是全方位全周期提升胸部肿瘤临床诊疗水平为目标，开展系列基础-临床-转化系列闭环研究。团队目前在读博士研究生9名、硕士研究生1名；毕业博士研究生3名、毕业硕士研究生3名。团队学生在Ann Oncol、J Thorac Oncol、 J Hematol Oncol、Clin Cancer Res 等国际一流期刊发表系列原创性研究，近5年在世界肺癌大会（IASLC WCLC）等国际顶级学术会议上作口头汇报12次，壁报展示27次，并荣获“第 12 届中国大 学生年度人物”提名奖、国家奖学金等国家级奖励 9 人次，上海市优秀毕业生等省部级荣誉 10 人次。目前已有多位毕业研究生成长为优秀的肿瘤科青年医师和研究者，并获国家自然科学基金 青年基金 3 项，上海市“扬帆计划”人才计划项目 2 项。此外，所在团队获得国家科技进步二等奖、IASLC-肿瘤团队治疗奖（CCTA）及上海市科技进步一等奖等多项荣誉。团队近5年发表的代表性论著如下：

(1) Wang, Yan; Jiang, Tao; Qin, Zhen; Jiang, Jiahua; Wang, Quanren; Yang, Shuo; Rivard, Chris; Gao, Guanghui; Ng, Terry L.; Tu, Megan M.; Yu, Hui; Ji, Hongbin; Zhou, Caicun; Ren, Shengxiang; Zhang, Jun; Bunn, Paul; Doebele, Robert C.; Camidge, D. Ross; Hirsch, Fred R ; HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib, Annals of Oncology, 2019, 30(3): 447-455 

(2) Nina G. Xie; Michael X. Wang; Ping Song; Shiqi Mao; Yifan Wang; Yuxia Yang; Junfeng Luo; Shengxiang Ren; David Yu Zhang ; Designing highly multiplex PCR primer sets with Simulated Annealing Design using Dimer Likelihood Estimation (SADDLE), Nature Communications, 2022, 13(1): DOI:10.1038/s41467-022-29500-4

(3) Tao Jiang; Pingyang Wang; Jie Zhang; Yanqiu Zhao; Jianying Zhou; Yun Fan; Yongqian Shu; Xiaoqing Liu; Helong Zhang; Jianxing He; Guanghui Gao; Xiaoqian Mu; Zhang Bao; Yanjun Xu; Renhua Guo; Hong Wang; Lin Deng; Ningqiang Ma; Yalei Zhang; Hui Feng; Sheng Yao; Jiarui Wu; Luonan Chen; Caicun Zhou; Shengxiang Ren ; Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial, Signal Transduction and Targeted Therapy, 2021, 6(1): DOI:10.1038/s41392-021-00751- 9

(4) Zhou, Caicun; Wang, Yina; Zhao, Jun; Chen, Gongyan; Liu, Zhihua; Gu, Kangsheng; Huang, Meijuan; He, Jianxing; Chen, Jianhua; Ma, Zhiyong; Feng, Jifeng; Shi, Jianhua; Yu, Xinmin; Cheng, Ying; Yao, Yu; Chen, Yuan; Guo, Renhua; Lin, Xiaoyan; Wang, Zhehai; Gao, Guanghui; Wang, Quanren; Li, Weixia; Yang, Xinfeng; Wu, Lihong; Zhang, Jun; Ren, Shengxiang ; Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy, Clinical Cancer Research, 2020, 27(5): 1296-1304

(5) Tao Jiang; Jianhua Chen; Xingxiang Xu; Ying Cheng; Gongyan Chen; Yueyin Pan; Yong Fang; Qiming Wang; Yunchao Huang; Wenxiu Yao; Rui Wang; Xingya Li; Wei Zhang; Yanjun Zhang; Sheng Hu; Renhua Guo; Jianhua Shi; Zhiwu Wang; Peiguo Cao; Donglin Wang; Jian Fang; Hui Luo; Yi Geng; Chunyan Xing; Dongqing Lv; Yiping Zhang; Junyan Yu; Shundong Cang; Yaxi Zhang; Jiao Zhang; Zeyu Yang; Wei Shi; Jianjun Zou; Caicun Zhou; Shengxiang Ren ; On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial, Molecular Cancer, 2022, 21(1): DOI:10.1186/s12943-021-01479-4

(6) Changsheng Huang; Shengxiang Ren; Yaqi Chen; Anyi Liu; Qi Wu; Tao Jiang; Panjing Lv; Da Song; Fuqing Hu; Jingqing Lan; Li Sun; Xue Zheng; Xuelai Luo; Qian Chu; Keyi Jia; Yan Li; Jun Wang; Caicun Zou; Junbo Hu; Guihua Wang ; PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance, Science Advances, 2023, 9(21)

(7) Shengxiang Ren; Jianhua Chen; Xingxiang Xu; Tao Jiang; Ying Cheng; Gongyan Chen; Yueyin Pan; Yong Fang; Qiming Wang; Yunchao Huang; Wenxiu Yao; Rui Wang; Xingya Li; Wei Zhang; Yanjun Zhang; Sheng Hu; Renhua Guo; Jianhua Shi; Zhiwu Wang; Peiguo Cao; Donglin Wang; Jian Fang; Hui Luo; Yi Geng; Chunyan Xing; Dongqing Lv; Yiping Zhang; Junyan Yu; Shundong Cang; Zeyu Yang; Wei Shi; Jianjun Zou; Caicun Zhou ; Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial, Journal of Thoracic Oncology, 2022, 17(4): 544-557

(8) Anwen Xiong; Shengxiang Ren; Huaimin Liu; Liyun Miao; Lei Wang; Jianhua Chen; Wei Li; Runpu Li; Xiang Wang; Zhiwei Lu; Donglin Wang; Xiaohong Wu; Zhihua Liu; Ligang Xing; Yimin Mao; Chunling Liu; Aiping Zeng; Hongrui Niu; Yingying Du; Yuping Sun; Yueyin Pan; Yanping Hu; Xiaodong Zhang; Xueqin Chen; Zhiyong Ma; Na Li; Jianyong Zhang; Min Zhao; Xiaoling Li; Feng Ye; Mingjun Li; Guohua Yu; Xiaomeng Zhang; Jie Min; Dong Han; Jin Li; Caicun Zhou ; Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial, Journal of Thoracic Oncology, 2022, 17(10): 1216-1226

(9) Meng Qiao; Tao Jiang; Xinyu Liu; Shiqi Mao; Fei Zhou; Xuefei Li; Chao Zhao; Xiaoxia Chen; Chunxia Su; Shengxiang Ren; Caicun Zhou ; Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?, Journal of Thoracic Oncology, 2021, 16(8): 1267-1288

(10) Jiang, Tao; Shi, Tao; Zhang, Henghui; Hu, Jie; Song, Yuanlin; Wei, Jia; Ren, Shengxiang; Zhou, Caicun ; Tumor neoantigens: from basic research to clinical applications, Journal of Hematology & Oncology, 2019, 12(1)

(11) Zhao, Sha; Ren, Shengxiang; Jiang, Tao; Zhu, Bo; Li, Xuefei; Zhao, Chao; Jia, Yijun; Shi, Jinpeng; Zhang, Limin; Liu, Xiaozhen; Qiao, Meng; Chen, Xiaoxia; Su, Chunxia; Yu, Hui; Zhou, Caicun; Zhang, Jun; Camidge, D Ross; Hirsch, Fred R ; Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer, Cancer Immunology Research, 2019, 7(4): 630-643

(12) Wang Yuetong; Zhang Jian; Ren Shengxiang; Sun Dan; Huang Hsin Yi; Wang Hua; Jin Yujuan; Li Fuming; Zheng Chao; Yang Liu; Deng Lei; Jiang Zhonglin; Jiang Tao; Han Xiangkun; Hou Shenda; Guo Chenchen; Li Fei; Gao Dong; Qin Jun; Gao Daming; Chen Luonan; Lin Shu Hai; Wong Kwok Kin; Li Cheng; Hu Liang; Zhou Caicun; Ji Hongbin ; Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors, Cell Reports, 2019, 28(2): 512- 525

主持国家级课题5项及省部级等各类课题22项，部分在研主持项目如下：

(1) 国家自然科学基金委员会, 面上项目, 82373319, HMGB1募集并驯化CCL8+肿瘤相关巨噬细胞介导EGFR突变 肺癌TKI耐药的机制研究，2024-01-01 至 2027-12-31, 48万元,  主持

(2) 国家自然科学基金委员会, 面上项目, 82172869, VEGFR2-TKI诱导铁死亡增强KEAP1突变肺癌PD-(L)1 单抗疗效的机制研究, 2022-01-01 至 2025-12-31, 55万元, 主持

(3) 国家自然科学基金委员会, 面上项目, 81972167, ALK融合基因调控CCL5表达影响非小细胞肺癌PD- 1/PD-L1单抗疗效的机制研究, 2020-01-01 至 2023-12-31, 54万元, 主持

(4) 上海市申康医院发展中心, 第二轮《促进市级医院临床技能与临床创新三年行动计划》研究型医师创新转化能力培训项目, SHDC2022CRT012, KRASG12D 突变肺癌治疗新策略的基础-临床 -转化研究, 2022-07 至 2024- 09, 300万元, 在研, 主持

(5) 上海市科学技术委员会, 上海市2021年度“科技创新行动计划”优秀学术/技术带头人计划项目/优 秀学术带头人(青年), 21XD1423200, 肺癌抗血管生成联合免疫治疗的临床和转化研究, 2021-09 至 2024- 08, 40万元, 在研, 主持

(1) 国家自然科学基金委员会, 面上项目, 82373319, HMGB1募集并驯化CCL8+肿瘤相关巨噬细胞介导EGFR突变肺癌TKI耐药的机制研究，2024-01-01 至 2027-12-31, 48万元, 在研, 主持

(2) 国家自然科学基金委员会, 面上项目, 82172869, VEGFR2-TKI诱导铁死亡增强KEAP1突变肺癌PD-(L)1单抗疗效的机制研究, 2022-01-01 至 2025-12-31, 55万元, 在研, 主持

(3) 国家自然科学基金委员会, 面上项目, 81972167, ALK融合基因调控CCL5表达影响非小细胞肺癌PD-1/PD-L1单抗疗效的机制研究, 2020-01-01 至 2023-12-31, 54万元, 在研, 主持

(4) 国家自然科学基金委员会, 面上项目, 81772467, VEGFR2-TKI重塑肿瘤微环境在增强非小细胞肺癌抗PD-1/PD-L1疗效中的机制研究, 2018-01-01 至 2021-12-31, 53万元, 结题, 主持

(5) 上海市申康医院发展中心, 第二轮《促进市级医院临床技能与临床创新三年行动计划》研究型医师创新转化能力培训项目, SHDC2022CRT012, KRASG12D 突变肺癌治疗新策略的基础-临床 -转化研究, 2022-07 至 2024-09, 300万元, 在研, 主持

(6) 上海市科学技术委员会, 上海市2021年度“科技创新行动计划”优秀学术/技术带头人计划项目/优秀学术带头人(青年), 21XD1423200, 肺癌抗血管生成联合免疫治疗的临床和转化研究, 2021-09 至 2024-08, 40万元, 在研, 主持

(7) 上海市申康医院发展中心, 市级医院新兴前沿技术联合攻关项目, SHDC12019133, 基于BDA-NGS技术指导晚期非小细胞肺癌液体活检及治疗的临床研究, 2019-11 至 2022-11, 50万元, 结题, 主持

(8) 上海市人力资源和社会保障局&上海市科学技术委员会, 上海市浦江人才计划, 2019PJD048, EZH2抑制剂重塑肿瘤免疫微环境增强非小细胞肺癌PD-1/PD-L1抗体免疫治疗疗效的机制研究, 2019-11 至 2021-10, 30万元, 结题, 主持

以通讯或第一（含共同）作者在Cancer Cell、Ann Oncol、Signal Transduct Target Ther、Mol Cancer、Sci Adv、Nat Commun、J Thorac Oncol、J Hemot Oncol、Clin Cancer Res等共发表SCI论文100余篇，他引9259，H指数47；执笔编写2019-2023《中国临床肿瘤学会非小细胞肺癌诊疗指南》，参与编写各类指南共识12篇，主编或参编著作9部；获得国家专利9项，其中发明专利4项；入选国家优秀青年医师、上海市优秀学术带头人、浦江人才、曙光人才计划等；获上海市科技进步一等奖（排名第2）、国家科技进步二等奖（排名第6）、IASLC-Fellowshipaward、IASLC-肿瘤治疗团队奖（代表亚洲）、US-CACA学者奖、上海市劳模、卫生系统“银蛇奖”、五四青年奖章等称号。

代表论著：

(1) Wang, Yan; Jiang, Tao; Qin, Zhen; Jiang, Jiahua; Wang, Quanren; Yang, Shuo; Rivard,Chris; Gao, Guanghui; Ng, Terry L.; Tu, Megan M.; Yu, Hui; Ji, Hongbin; Zhou, Caicun; Ren,Shengxiang; Zhang, Jun; Bunn, Paul; Doebele, Robert C.; Camidge, D. Ross; Hirsch, Fred R ; HER2exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HERreceptor tyrosine kinase inhibitor pyrotinib, Annals of Oncology, 2019, 30(3): 447-455 

(2) Nina G. Xie; Michael X. Wang; Ping Song; Shiqi Mao; Yifan Wang; Yuxia Yang; Junfeng Luo;Shengxiang Ren; David Yu Zhang ; Designing highly multiplex PCR primer sets with SimulatedAnnealing Design using Dimer Likelihood Estimation (SADDLE), Nature Communications, 2022, 13(1):DOI:10.1038/s41467-022-29500-4

(3) Tao Jiang; Pingyang Wang; Jie Zhang; Yanqiu Zhao; Jianying Zhou; Yun Fan; Yongqian Shu;Xiaoqing Liu; Helong Zhang; Jianxing He; Guanghui Gao; Xiaoqian Mu; Zhang Bao; Yanjun Xu; RenhuaGuo; Hong Wang; Lin Deng; Ningqiang Ma; Yalei Zhang; Hui Feng; Sheng Yao; Jiarui Wu; Luonan Chen;Caicun Zhou; Shengxiang Ren ; Toripalimab plus chemotherapy as second-line treatment inpreviously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-IItrial, Signal Transduction and Targeted Therapy, 2021, 6(1): DOI:10.1038/s41392-021-00751-9

(4) Zhou, Caicun; Wang, Yina; Zhao, Jun; Chen, Gongyan; Liu, Zhihua; Gu, Kangsheng; Huang,Meijuan; He, Jianxing; Chen, Jianhua; Ma, Zhiyong; Feng, Jifeng; Shi, Jianhua; Yu, Xinmin; Cheng,Ying; Yao, Yu; Chen, Yuan; Guo, Renhua; Lin, Xiaoyan; Wang, Zhehai; Gao, Guanghui; Wang, Quanren;Li, Weixia; Yang, Xinfeng; Wu, Lihong; Zhang, Jun; Ren, Shengxiang ; Efficacy and BiomarkerAnalysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLCPreviously Treated with Chemotherapy, Clinical Cancer Research, 2020, 27(5): 1296-1304

(5) Tao Jiang; Jianhua Chen; Xingxiang Xu; Ying Cheng; Gongyan Chen; Yueyin Pan; Yong Fang;Qiming Wang; Yunchao Huang; Wenxiu Yao; Rui Wang; Xingya Li; Wei Zhang; Yanjun Zhang; Sheng Hu;Renhua Guo; Jianhua Shi; Zhiwu Wang; Peiguo Cao; Donglin Wang; Jian Fang; Hui Luo; Yi Geng;Chunyan Xing; Dongqing Lv; Yiping Zhang; Junyan Yu; Shundong Cang; Yaxi Zhang; Jiao Zhang; ZeyuYang; Wei Shi; Jianjun Zou; Caicun Zhou; Shengxiang Ren ; On-treatment blood TMB as predictorsfor camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysisof a phase III trial, Molecular Cancer, 2022, 21(1): DOI:10.1186/s12943-021-01479-4

(6) Changsheng Huang; Shengxiang Ren; Yaqi Chen; Anyi Liu; Qi Wu; Tao Jiang; Panjing Lv; DaSong; Fuqing Hu; Jingqing Lan; Li Sun; Xue Zheng; Xuelai Luo; Qian Chu; Keyi Jia; Yan Li; JunWang; Caicun Zou; Junbo Hu; Guihua Wang ; PD-L1 methylation restricts PD-L1/PD-1 interactions tocontrol cancer immune surveillance, Science Advances, 2023, 9(21)

(7) Shengxiang Ren; Jianhua Chen; Xingxiang Xu; Tao Jiang; Ying Cheng; Gongyan Chen; YueyinPan; Yong Fang; Qiming Wang; Yunchao Huang; Wenxiu Yao; Rui Wang; Xingya Li; Wei Zhang; YanjunZhang; Sheng Hu; Renhua Guo; Jianhua Shi; Zhiwu Wang; Peiguo Cao; Donglin Wang; Jian Fang; HuiLuo; Yi Geng; Chunyan Xing; Dongqing Lv; Yiping Zhang; Junyan Yu; Shundong Cang; Zeyu Yang; WeiShi; Jianjun Zou; Caicun Zhou ; Camrelizumab Plus Carboplatin and Paclitaxel as First-LineTreatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial, Journal of Thoracic Oncology,2022, 17(4): 544-557

(8) Anwen Xiong; Shengxiang Ren; Huaimin Liu; Liyun Miao; Lei Wang; Jianhua Chen; Wei Li;Runpu Li; Xiang Wang; Zhiwei Lu; Donglin Wang; Xiaohong Wu; Zhihua Liu; Ligang Xing; Yimin Mao;Chunling Liu; Aiping Zeng; Hongrui Niu; Yingying Du; Yuping Sun; Yueyin Pan; Yanping Hu; XiaodongZhang; Xueqin Chen; Zhiyong Ma; Na Li; Jianyong Zhang; Min Zhao; Xiaoling Li; Feng Ye; MingjunLi; Guohua Yu; Xiaomeng Zhang; Jie Min; Dong Han; Jin Li; Caicun Zhou ; Efficacy and Safety ofSH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase2 Trial, Journal of Thoracic Oncology, 2022, 17(10): 1216-1226

(9) Meng Qiao; Tao Jiang; Xinyu Liu; Shiqi Mao; Fei Zhou; Xuefei Li; Chao Zhao; Xiaoxia Chen;Chunxia Su; Shengxiang Ren; Caicun Zhou ; Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC:Dusk or Dawn?, Journal of Thoracic Oncology, 2021, 16(8): 1267-1288

(10) Jiang, Tao; Shi, Tao; Zhang, Henghui; Hu, Jie; Song, Yuanlin; Wei, Jia; Ren, Shengxiang;Zhou, Caicun ; Tumor neoantigens: from basic research to clinical applications, Journal ofHematology & Oncology, 2019, 12(1)

(11) Zhao, Sha; Ren, Shengxiang; Jiang, Tao; Zhu, Bo; Li, Xuefei; Zhao, Chao; Jia, Yijun; Shi,Jinpeng; Zhang, Limin; Liu, Xiaozhen; Qiao, Meng; Chen, Xiaoxia; Su, Chunxia; Yu, Hui; Zhou,Caicun; Zhang, Jun; Camidge, D Ross; Hirsch, Fred R ; Low-Dose Apatinib Optimizes TumorMicroenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer, CancerImmunology Research, 2019, 7(4): 630-643

(12) Wang Yuetong; Zhang Jian; Ren Shengxiang; Sun Dan; Huang Hsin Yi; Wang Hua; Jin Yujuan;Li Fuming; Zheng Chao; Yang Liu; Deng Lei; Jiang Zhonglin; Jiang Tao; Han Xiangkun; Hou Shenda;Guo Chenchen; Li Fei; Gao Dong; Qin Jun; Gao Daming; Chen Luonan; Lin Shu Hai; Wong Kwok Kin; LiCheng; Hu Liang; Zhou Caicun; Ji Hongbin ; Branched-Chain Amino Acid Metabolic ReprogrammingOrchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors, Cell Reports, 2019, 28(2): 512-525